Global Health Sciences Fund (Quark Venture LP and GF Securities) Participates in $25 Million Financing for EyeYon Medical’s EndoArt® Clinical Trials Across Three Continents
15. März 2021 13:05 ET
|
Quark Venture LP
VANCOUVER, British Columbia, March 15, 2021 (GLOBE NEWSWIRE) -- Quark Venture LP (Quark) and GF Securities participated in the $25 million financing of EyeYon Medical, to advance its EndoArt®...
Global Health Sciences Fund (Quark Venture LP and GF Securities) Announces Portfolio Company SQZ Biotechnologies’ IPO
09. November 2020 08:00 ET
|
Quark Venture LP; Global Health Sciences Fund
VANCOUVER, British Columbia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Quark Venture LP (Quark) and GF Securities are pleased to announce the successful listing of portfolio company, SQZ Biotechnologies...
Global Health Sciences Fund (Quark Venture LP and GF Securities) Contributes to Volastra Therapeutics’ $12 Million Seed Financing for Company’s Development of Novel Metastatic Cancer Therapies
11. Februar 2020 08:33 ET
|
Quark Venture
VANCOUVER, British Columbia, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Quark Venture LP and GF Securities today announced that they have contributed to the $12 million seed financing to launch Volastra...
Global Health Sciences Fund (Quark Venture LP and GF Securities) Participates in $22 Million Series C Preferred Stock Financing in Raziel Therapeutics for Development of an Orphan Drug Treating Fat Disorders
28. Januar 2020 09:00 ET
|
Quark Venture
VANCOUVER, British Columbia, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Quark Venture LP and GF Securities participated in the $22 million Series C financing announced in December 2019 for Raziel...
Quark Venture Inc. and GF Securities Participate in Keros Therapeutics’ $23 million Series B Financing for Development of Therapies to Treat Debilitating Neuromuscular Diseases
07. Januar 2019 09:00 ET
|
Quark Venture
VANCOUVER, British Columbia, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Quark Venture Inc. (Quark) and GF Securities are pleased to announce their investment in Keros Therapeutics, a company dedicated to the...
Quark defends its decision to cease further funding of MSI’s lead compound
16. Oktober 2018 09:00 ET
|
Quark Venture
VANCOUVER, British Columbia, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Quark Venture Inc. (“Quark”) has petitioned the British Columbia Supreme Court to overturn an unfavourable arbitration award concerning...
New medical device platform takes flight: Global Health Sciences Fund invests in Canary Medical’s proprietary, “smart” implant technology designed to improve outcomes in post-surgical patients
17. Mai 2018 13:06 ET
|
Quark Venture
VANCOUVER, British Columbia, May 17, 2018 (GLOBE NEWSWIRE) -- Today, Quark Venture Inc. and GF Securities, through their Global Health Sciences Fund (GHS), announced a US$10 million investment in...
ARTMS Products Inc. Raises US$3 Million to Advance a Safe Alternative Way to Locally Produce Medical Isotopes and Avoid Future Supply Disruptions
18. Dezember 2017 09:00 ET
|
Quark Venture
VANCOUVER, British Columbia, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Today, ARTMS Products Inc., the leader in the development of novel technologies which enable the production of the world’s most-used...
First Meeting of Health and Biosciences Economic Strategy Table identifies Canada with potential to be global economic powerhouse
10. November 2017 17:16 ET
|
Quark Venture
VANCOUVER, British Columbia, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Karimah Es Sabar, CEO and Partner, Quark Venture, chaired the first Health and Biosciences Economic Strategy Table meeting in...
Quark Venture and GF Securities Invest in Digital Technology Platform That Provides Physicians With Non-Invasive Evidence Supporting Decisions in Coronary Interventions
05. Oktober 2017 11:55 ET
|
Quark Venture; GF Securities
VANCOUVER, British Columbia, Oct. 05, 2017 (GLOBE NEWSWIRE) -- Today, Quark Venture Inc. and GF Securities announced a US$5 million investment in CathWorks Ltd, a leader in developing non-invasive...